Firefly Neuroscience (NASDAQ: AIFF) has announced the identification of a novel electrophysiological biomarker for Post-Traumatic Stress Disorder (PTSD) using brain scans collected on its FDA-510(k)-cleared Evoke System.
The biomarker discovery emanates partly from Firefly’s previously announced public-private partnership with the U.S. Department of War (DoW) to support the assessment and treatment of active-duty U.S. service members and veterans suffering from PTSD and/or Traumatic Brain Injury (TBI).
PTSD affects approximately 13 million Americans in any given year, and about 6% of the U.S. population will have PTSD at some point in their life. The disorder is disproportionately prevalent in military personnel; with 11–20% of Operation Iraqi Freedom and Enduring Freedom veterans experiencing PTSD annually. The total U.S. economic burden of PTSD has been estimated at $232.2 billion, of which $42.7 billion is attributed directly to the military population.
The biomarker discovery leverages Firefly’s deep learning architecture running on NVIDIA L40S GPU-accelerated infrastructure, enabling high-throughput analysis of multi-channel electroencephalogram (EEG) and Event-Related Potential (ERP) waveforms at unprecedented scale. The Evoke System’s dual-signal approach, capturing both resting-state hyperarousal patterns and abnormal cognitive ERP responses, is particularly well-suited to PTSD diagnostics.
In a statement, Gil Issachar, CTO of Firefly, commented, “By applying our AI models to a dataset that we believe to be unmatched in scale, we have identified a consistent and reproducible electrophysiological pattern distinguishing PTSD patients from healthy controls. Given our previously announced DoW deployment, this discovery holds potential for providing military healthcare providers with not just a powerful assessment tool, but a scientifically grounded neural signal to anchor it.”
Greg Lipschitz, Firefly’s CEO, said, “Our proprietary database is an important asset that continues to generate breakthrough cognitive brain biomarker discoveries. The convergence of this PTSD biomarker finding with our previously announced DoW partnership represents a significant milestone: we are deploying FDA-cleared technology to support the assessment and treatment of active-duty U.S. service members and veterans while, at the same time, generating the neuroscience that could support how PTSD is objectively assessed for both them and civilians going forward. Our NVIDIA L40S GPU-accelerated foundation model architecture creates a potential competitive advantage in biomarker discovery that we believe positions Firefly well across defense health, pharma partnerships, and clinical psychiatry.”
This biomarker discovery further advances Firefly’s mission to build the world’s first EEG/ERP-based brain foundation model, a large-scale AI architecture trained across all disorder categories to serve as a universal brain health intelligence platform for neurology, psychiatry, and drug development.
